Ontology highlight
ABSTRACT:
SUBMITTER: Nakahara M
PROVIDER: S-EPMC9468852 | biostudies-literature | 2022 Oct
REPOSITORIES: biostudies-literature

Nakahara Mai M Fujihara Shintaro S Iwama Hisakazu H Takuma Kei K Oura Kyoko K Tadokoro Tomoko T Fujita Koji K Tani Joji J Morishita Asahiro A Kobara Hideki H Himoto Takashi T Masaki Tsutomu T
Biomedical reports 20220803 4
Lenvatinib is a tyrosine kinase receptor inhibitor used to treat unresectable hepatocellular carcinoma (HCC). In this study, we investigated the antitumor effects of Lenvatinib treatment on HCC cell lines. Proliferation was examined in four HCC cell lines (HuH-7, Hep3B, Li-7, and PLC/PRF/5) using Cell Counting Kit-8 assays. Xenograft mouse models were used to assess the effects of Lenvatinib <i>in vivo</i>. Cell cycle, western blotting, and microRNA (miRNA) expression analyses were performed to ...[more]